Comment on ‘Drug reaction with eosinophilia and systemic symptoms syndrome in a patient with COVID‐19’: involvement of herpesvirus reactivations and adverse drug reactions in diverse cutaneous manifestations and overall disease severity of COVID‐19

We have read with great interest the publication by Herman, et al., which reported occurrence of drug reaction with eosinophilia and systemic symptoms (DRESS), also known as drug‐induced hypersensitivity syndrome (DiHS), in a COVID‐19 patient:1 the patient developed DiHS/DRESS 17~18 days after starting azithromycin and hydroxychloroquine.